Alpha blockers improve stone passage rates, decrease time to expulsion
By Sara L. Best, MD, and
Stephen Y. Nakada, MD
IN 2007, an international panel convened by the American Urological Association (AUA) and the European Association of Urology (EAU) updated the AUA ureteral stone guidelines. Most notably, the new guidelines reflect a pragmatic addition to the urologist's armamentarium: medical expulsive therapy (MET). MET is defined as the use of pharmaceutical agents to improve urinary stone passage rates and the time to stone passage in select individuals.
Most small stones will pass spontaneously without the need for intervention. From 71%-98% of stones less than 5 mm in size will pass without surgery.1 However, stones can induce ureteral spasm, which can hinder stone passage.2 The ureter has several types of receptors and cell to cell interactions that may play a role.
Alpha receptors are present in the human ureter, and selective alpha blockers such as tamsulosin have been shown to inhibit basal tone and decrease the frequency and amplitude of peristalsis in the ureter.3 The AUA/EAU guidelines included a meta-analysis of the randomized controlled trials (RCT) available evaluating alpha blockers as medical expulsive agents. This analysis found that use of MET significantly increased stone passage rate by 29%.4 One study compared three available alpha blockers (tamsulosin, terazosin, and doxazosin) in a clinical RCT and found similar stone passage rates among them.5
Not only do alpha blockers appear to improve stone passage rates, but they also decrease the time to stone expulsion. A study by Porpiglia et al compared tamsulosin to nifedipine in 86 patients with distal ureteral calculi measuring less than 1 cm. Patients were randomized to receive deflazacort (a corticosteroid) with either nifedipine or tamsulosin or to a control group. Stone passage was observed in 80% in the nifedipine group, 85% in the tamsulosin group and 43% in the control group. Average expulsion time was 9.3, 7.7 and 12 days for the three groups, respectively.6
The majority of the published RCTs combined a corticosteroid with an alpha blocker to improve spontaneous stone passage rates. Dellabella et al evaluated the efficacy of tamsulosin with deflazacort in patients with distal stones. Sixty patients were randomized to receive a combination of phloroglucinol-trimethoxybenzene (an oral antispasmolytic), deflazacort, and cotrimoxazole, or this combination plus tamsulosin 0.4 mg daily. The tamsulosin group showed a significantly higher stone-expulsion rate (100% vs. 70%) and a shorter stone expulsion time (65.7 vs. 111.1 hours). No drug-related side effects were reported and hospital stays were dramatically decreased in the tamsulosin group.7
The benefits of alpha blockers are not just limited to stone patients who are able to take corticosteroids concurrently. A meta-analysis of the available MET data by Hollingsworth et al suggests that the additive benefit of corticosteroids as an adjunct to alpha blocker therapy is small, and that MET also provided the advantage of fewer pain episodes, lower analogue pain scores, and lower analgesic dose requirements.8
Dellabella et al described the additional benefit of steroids as an increase in expulsion rate from 90% with tamsulosin alone to 96.7% in patients receiving the alpha blocker plus deflazacort. The patients taking the tamsulosin/deflazacort combination also decreased their time to stone passage to 72 hours compared with 120 hours in those on tamsulosin monotherapy. They concluded that both regimens were highly effective.9
These studies, along with others, have made tamsulosin a commonly used agent. The rationale for this is based on efficacy, tolerability, and the comfort level urologists have in using tamsulosin for BPH management.
Calcium channel blockers have also been investigated for MET. Ureteral smooth muscle contraction is mediated by calcium channels and therefore drugs such as nifedipine theoretically should decrease ureteral spasm and improve stone passage. As mentioned previously, Dellabella et al showed an 80% stone passage rate in patients taking nifedipine, as compared to 43% of control patients.7 The meta-analysis by the AUA/EAU Ureteral Stone Guidelines panel showed an overall improvement in stone expulsion of only 9%, which was not statistically significant.4
The panel suggests advising appropriate patients with stones less than 10 mm in size of the availability of MET as well as the side effects, and that MET is an “off label” use of these medications. Patients should be followed closely with periodic imaging and “should have well-controlled pain, no clinical evidence of sepsis, and adequate renal functional reserve.” Surgical intervention would be indicated if obstruction persists, the stone fails to progress towards passage, or in the setting of worsening pain.4
The advantages of MET are clear and not strictly limited to improved stone passage rates. This modality may decrease patient exposure to the morbidities and complications of both ureteroscopy and shock wave lithotripsy. Ongoing studies are looking at the likely potential economic benefits of MET in decreasing health care expenditures as well as lost work days of patients suffering from nephrolithiasis. Still, not all urologists seem to have hopped on this bandwagon. We performed a regional survey of urologists showing that only 32% of respondents would use MET to manage distal ureteral stones less than 5 mm in size, despite literature suggesting otherwise.10
In 2005, Chang and Campbell identified a link between tamsulosin and billowing and prolapse of the iris during cataract surgery termed “intra-operative floppy iris syndrome.”11 Current recommendations are to advise tamsulosin patients to stop taking the drug prior to cataract surgery.12 In spite of this, medical expulsive therapy is a effective off-label treatment option for many stone patients. Further studies will help define the cost, side effects, and range of utility of MET, but in the meantime it appears to be here to stay.
Sara L. Best, MD, is a senior resident in urology and Stephen Y. Nakada, MD, is professor and chairman of urology at the University of Wisconsin School of Medicine and Public Health in Madison.
References
1. Ibrahim AI, Shetty SD, Awad RM, Patel KP. Prognostic factors in the conservative treatment of ureteric stones. Br J Urol. 1991;67:358-361.
2. Peters HJ, Eckstein W. Possible pharmacological means of treating renal colic. Urol Res. 1975;3:55-59.
3. Nakada SY, Hedican SP, Moon TD, et al. Doxazosin relaxes ureteral smooth muscle and reverses epinephrine-induced ureteral contractility. J Urol. suppl.2005. 173:299, abstract 104.
4. Preminger GM, Tiselius HG, Assimos DG, et al. EAU/AUA Nephrolithiasis Guideline Panel. 2007 guideline for the management of ureteral calculi. J Urol. 2007;178:2418-2434.
5. Yilmaz E, Batislam E, Basar MM, et al. The comparison and efficacy of 3 different alpha1-adrenergic blockers for distal ureteral stones. J Urol. 2005;173:2010-2012.
6. Porpiglia F, Ghignone G, Fiori C, et al. Nifedipine versus tamsulosin for the management of lower ureteral stones. J Urol. 2004;172:568-571.
7. Dellabella M, Milanese G, Muzzonigro G. Efficacy of tamsulosin in the medical management of juxtavesical ureteral stones. J Urol. 2003;170:2202-2205.
8. Hollingsworth JM, Rogers MA, Kaufman SR, et al. Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet. 2006;368:1171-1179.
9. Dellabella M, Milanese G, Muzzonigro G. Randomized trial of the efficacy of tamsulosin, nifedipine and phloroglucinol in medical expulsive therapy for distal ureteral calculi. J Urol. 2005;174:167-172.
10. Bandi G, Best SL, Nakada SY. Current practice patterns in management of upper urinary tract calculi in the north-central United States. J Endo. In press.
11. Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg. 2005;31:664-673.
12. Chang DF, Osher RH, Wang L, Koch DD. Prospective multicenter evaluation of cataract surgery in patients taking tamsulosin (Flomax). Ophthalmology. 2007;114:957-964.